Cite
HARVARD Citation
Chen, B. et al. (n.d.). DOP01 Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative Colitis. Journal of Crohn's and colitis. pp. S041-S042. [Online].